Global Oncology Market Expected to Reach $748.17 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Source: PRnewswire
- Market Growth Potential: The global oncology market is projected to grow from $279.98 billion in 2026 to $748.17 billion by 2035, indicating strong growth potential and reflecting the ongoing demand for cancer treatments.
- Innovation-Driven Revenue: Cancer drug revenues are expected to reach $335.2 billion by 2033, primarily driven by the adoption of targeted therapies and immunotherapy, indicating a significant shift towards more effective treatment options in the industry.
- Clinical Trial Advancements: Oncolytics Biotech is focusing on registrational programs in anal and colorectal cancer, planning to meet with the FDA in mid-April, and expects to secure approval through a clinical trial involving fewer than 100 subjects, showcasing its strategic advantage in rare cancer indications.
- Strong Clinical Results: In third-line anal cancer patients, pelareorep achieved a 29% response rate, while in second-line or later patients, the response rate was 30%, significantly exceeding the benchmark for FDA-approved immunotherapies, highlighting its potential in treatment efficacy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to rise
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 115.480
Low
95.00
Averages
119.53
High
139.00
Current: 115.480
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of FDL's 52-Week High and Low Points
- Price Fluctuation Analysis: FDL's 52-week low is $41.515 and high is $51.46, with the latest trade at $49.41, indicating price volatility within this range that may influence investor buying decisions.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding helps identify those experiencing notable inflows (new units created) or outflows (old units destroyed), allowing assessment of their impact on underlying assets.
See More
Pfizer's Cancer Drug Trial Results Mixed Yet Promising
- Trial Result Analysis: Pfizer's investigational antibody-drug conjugate sigvotatug vedotin failed to demonstrate a statistically significant improvement in overall survival compared to docetaxel in the SigVie-002 study involving 703 previously treated non-small cell lung cancer patients, resulting in the primary endpoint not being met.
- Subgroup Performance: Despite the overall disappointing results, sigvotatug vedotin showed promising signals for overall survival and progression-free survival in a prespecified subgroup of patients who had received only one prior line of therapy, indicating potential efficacy in this specific population.
- Manageable Safety Profile: Pfizer reported that the safety profile of sigvotatug vedotin was consistent with earlier studies and manageable, which provides confidence for its use in historically difficult-to-treat patient populations.
- Future Research Directions: Pfizer plans to present detailed results from the SigVie-002 study at an upcoming medical congress and is conducting ongoing late-stage trials evaluating sigvotatug vedotin in combination with Merck's pembrolizumab, reflecting the company's commitment to advancing cancer treatment options.
See More
Merck's Capvaxive Vaccine Approved for Children by FDA
- Vaccine Label Expansion: Merck announced that its pneumococcal vaccine Capvaxive has received FDA approval for use in children aged 2 to 17, marking a significant expansion into the pediatric immunization market.
- Eligibility Criteria: The newly approved label stipulates that eligible children must have completed a primary pneumococcal vaccination series and have at least one chronic medical condition, ensuring the vaccine's effectiveness and safety for high-risk groups.
- Market Exclusivity: Capvaxive is now the only pneumococcal conjugate vaccine approved for this age group in the U.S., enhancing Merck's competitive position in the pediatric vaccine market and potentially driving sales growth.
- Strategic Implications: This approval not only broadens Capvaxive's market potential but also lays the groundwork for Merck's ongoing innovation and development in the vaccine sector, expected to boost overall company performance and shareholder returns.
See More
FDA Approves CAPVAXIVE Vaccine for Children at Risk
- FDA Approval for Expanded Indication: Merck announced that CAPVAXIVE has received FDA approval for use in children aged 2 to 17 with chronic conditions, providing additional protection and covering approximately 79% of invasive pneumococcal disease cases, significantly enhancing public health safety.
- Clinical Trial Support: Based on data from the Phase 3 STRIDE-13 trial, CAPVAXIVE demonstrated superior immune responses compared to PPSV23, showing significant protective effects against nine unique serotypes, thereby enhancing the vaccine's market competitiveness.
- Vaccine Coverage Scope: The 11 unique serotypes targeted by CAPVAXIVE account for 40% of invasive pneumococcal disease cases, highlighting its importance in high-risk pediatric populations and addressing unmet public health needs.
- Strategic Significance: This approval not only showcases Merck's commitment to public health but also provides a new preventive measure for children and adolescents, further solidifying the company's leadership position in the vaccine market.
See More
MoonLake Immunotherapeutics Set for Key Clinical Data Release
- Clinical Trial Progress: MoonLake's two large late-stage trials for hidradenitis suppurativa involved approximately 838 patients, with one trial meeting its primary goal while the other narrowly missed due to an unusually high placebo response rate, highlighting the complexity of clinical outcomes.
- Data Release Expectations: Full 52-week results from both trials are anticipated in Q2 2026, which will help assess the drug's long-term efficacy and could significantly impact future market performance.
- Acquisition Rumors: Merck is viewed as a potential acquirer of MoonLake, having made a non-binding offer exceeding $3 billion in 2025, which was rejected by MoonLake, yet discussions may resume, indicating strong market interest in the company.
- Investor Sentiment Shift: Over the past 24 hours, retail sentiment around MLTX shifted from 'bearish' to 'bullish', with message volume rising significantly, reflecting investor optimism regarding the upcoming clinical data, which could drive stock price increases.
See More
Gilead's HIV Prevention Drug Filing Accepted by FDA
- FDA Filing Accepted: Gilead Sciences announced that the FDA has accepted its supplemental new drug application for the weekly oral HIV prevention drug Yeztugo, with a target action date of February 2, 2027, which will provide a more convenient prevention option for high-risk populations and further solidify its leadership in the HIV market.
- Clinical Data Support: The application for Yeztugo is backed by data from the PURPOSE 1 and PURPOSE 2 studies, demonstrating the strong efficacy of lenacapavir across diverse populations, successfully addressing the needs of different patients and potentially increasing Gilead's market share in HIV prevention.
- Sales Forecast Increase: Gilead has raised its 2026 sales forecast for Yeztugo to $1 billion, indicating confidence in the drug's market acceptance and sales potential, with expectations for it to achieve blockbuster status in its first full year post-launch.
- Collaborative Research Progress: Positive results from Gilead's collaboration with Merck in the ISLEND-1 and ISLEND-2 studies support the potential of a new once-weekly oral single-tablet treatment regimen, further advancing Gilead's HIV treatment pipeline and enhancing its competitive position in the market.
See More
Analysis of FDL's 52-Week High and Low Points
- Price Fluctuation Analysis: FDL's 52-week low is $41.515 and high is $51.46, with the latest trade at $49.41, indicating price volatility within this range that may influence investor buying decisions.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding helps identify those experiencing notable inflows (new units created) or outflows (old units destroyed), allowing assessment of their impact on underlying assets.
See More
Pfizer's Cancer Drug Trial Results Mixed Yet Promising
- Trial Result Analysis: Pfizer's investigational antibody-drug conjugate sigvotatug vedotin failed to demonstrate a statistically significant improvement in overall survival compared to docetaxel in the SigVie-002 study involving 703 previously treated non-small cell lung cancer patients, resulting in the primary endpoint not being met.
- Subgroup Performance: Despite the overall disappointing results, sigvotatug vedotin showed promising signals for overall survival and progression-free survival in a prespecified subgroup of patients who had received only one prior line of therapy, indicating potential efficacy in this specific population.
- Manageable Safety Profile: Pfizer reported that the safety profile of sigvotatug vedotin was consistent with earlier studies and manageable, which provides confidence for its use in historically difficult-to-treat patient populations.
- Future Research Directions: Pfizer plans to present detailed results from the SigVie-002 study at an upcoming medical congress and is conducting ongoing late-stage trials evaluating sigvotatug vedotin in combination with Merck's pembrolizumab, reflecting the company's commitment to advancing cancer treatment options.
See More
Merck's Capvaxive Vaccine Approved for Children by FDA
- Vaccine Label Expansion: Merck announced that its pneumococcal vaccine Capvaxive has received FDA approval for use in children aged 2 to 17, marking a significant expansion into the pediatric immunization market.
- Eligibility Criteria: The newly approved label stipulates that eligible children must have completed a primary pneumococcal vaccination series and have at least one chronic medical condition, ensuring the vaccine's effectiveness and safety for high-risk groups.
- Market Exclusivity: Capvaxive is now the only pneumococcal conjugate vaccine approved for this age group in the U.S., enhancing Merck's competitive position in the pediatric vaccine market and potentially driving sales growth.
- Strategic Implications: This approval not only broadens Capvaxive's market potential but also lays the groundwork for Merck's ongoing innovation and development in the vaccine sector, expected to boost overall company performance and shareholder returns.
See More
FDA Approves CAPVAXIVE Vaccine for Children at Risk
- FDA Approval for Expanded Indication: Merck announced that CAPVAXIVE has received FDA approval for use in children aged 2 to 17 with chronic conditions, providing additional protection and covering approximately 79% of invasive pneumococcal disease cases, significantly enhancing public health safety.
- Clinical Trial Support: Based on data from the Phase 3 STRIDE-13 trial, CAPVAXIVE demonstrated superior immune responses compared to PPSV23, showing significant protective effects against nine unique serotypes, thereby enhancing the vaccine's market competitiveness.
- Vaccine Coverage Scope: The 11 unique serotypes targeted by CAPVAXIVE account for 40% of invasive pneumococcal disease cases, highlighting its importance in high-risk pediatric populations and addressing unmet public health needs.
- Strategic Significance: This approval not only showcases Merck's commitment to public health but also provides a new preventive measure for children and adolescents, further solidifying the company's leadership position in the vaccine market.
See More
MoonLake Immunotherapeutics Set for Key Clinical Data Release
- Clinical Trial Progress: MoonLake's two large late-stage trials for hidradenitis suppurativa involved approximately 838 patients, with one trial meeting its primary goal while the other narrowly missed due to an unusually high placebo response rate, highlighting the complexity of clinical outcomes.
- Data Release Expectations: Full 52-week results from both trials are anticipated in Q2 2026, which will help assess the drug's long-term efficacy and could significantly impact future market performance.
- Acquisition Rumors: Merck is viewed as a potential acquirer of MoonLake, having made a non-binding offer exceeding $3 billion in 2025, which was rejected by MoonLake, yet discussions may resume, indicating strong market interest in the company.
- Investor Sentiment Shift: Over the past 24 hours, retail sentiment around MLTX shifted from 'bearish' to 'bullish', with message volume rising significantly, reflecting investor optimism regarding the upcoming clinical data, which could drive stock price increases.
See More
Gilead's HIV Prevention Drug Filing Accepted by FDA
- FDA Filing Accepted: Gilead Sciences announced that the FDA has accepted its supplemental new drug application for the weekly oral HIV prevention drug Yeztugo, with a target action date of February 2, 2027, which will provide a more convenient prevention option for high-risk populations and further solidify its leadership in the HIV market.
- Clinical Data Support: The application for Yeztugo is backed by data from the PURPOSE 1 and PURPOSE 2 studies, demonstrating the strong efficacy of lenacapavir across diverse populations, successfully addressing the needs of different patients and potentially increasing Gilead's market share in HIV prevention.
- Sales Forecast Increase: Gilead has raised its 2026 sales forecast for Yeztugo to $1 billion, indicating confidence in the drug's market acceptance and sales potential, with expectations for it to achieve blockbuster status in its first full year post-launch.
- Collaborative Research Progress: Positive results from Gilead's collaboration with Merck in the ISLEND-1 and ISLEND-2 studies support the potential of a new once-weekly oral single-tablet treatment regimen, further advancing Gilead's HIV treatment pipeline and enhancing its competitive position in the market.
See More
